April, 2011, Business Review USA
C2N Diagnostics is at the forefront of innovation and technology with respect to the analysis of how neurodegenerative disorders impair normal biological processes within the brain. The tools developed and deployed at C2N allow for the rapid testing of new drugs in development, designed to prevent or revert underlying disease processes.
C2N Diagnostics offers a portfolio of bioanalytical research services and tools to pharmaceutical and biotechnology companies. These companies employ C2N to evaluate new therapies in development for brain disorders like Alzheimer’s and Parkinson’s diseases. C2N also applies its technology to better understand the causes of these diseases and to enable their early stage detection.